Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials

Abstract Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. Th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d65c9a48207b4b24bfd98f68dab00c09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!